<DOC>
	<DOCNO>NCT00316875</DOCNO>
	<brief_summary>RATIONALE : Lapatinib may stop growth tumor cell block enzymes need cell growth . Drugs use chemotherapy , doxorubicin hydrochloride liposome work different way stop growth tumor cell , either kill cell stop divide . Giving lapatinib together doxorubicin hydrochloride liposome may kill tumor cell . PURPOSE : This phase I trial study side effect best dose doxorubicin hydrochloride liposome give together lapatinib treat patient metastatic breast cancer .</brief_summary>
	<brief_title>Lapatinib Doxorubicin Hydrochloride Liposome Treating Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Evaluate safety , tolerability , feasibility pegylated doxorubicin HCl liposome ( PLD ) administer lapatinib , particularly term cardiac safety , patient metastatic breast cancer . - Determine optimally tolerate regimen ( OTR ) PLD administer lapatinib patient . Secondary - Determine pharmacokinetic profile lapatinib PLD give combination OTR . - Describe preliminary evidence efficacy lapatinib PLD patient . OUTLINE : This open-label , dose-escalation study pegylated doxorubicin HCl liposome ( PLD ) . Patients receive oral lapatinib daily day 1-28 PLD IV least 30 minute day 1 . Treatment repeat every 28 day 8 course absence disease progression unacceptable toxicity . Lapatinib may continue alone absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos PLD maximum tolerate dose ( MTD ) determine . The MTD define dose precede 3 6 patient experience dose-limiting toxicity . After complete study treatment , patient follow 30 day . PROJECTED ACCRUAL : A total 25 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma breast evidence metastatic disease Epidermal growth factor receptor ( EGFR ) and/or erbB2 positivity require Measurable disease , define ≥ 1 lesion accurately measure ≥ 1 dimension ≥ 20 mm conventional technique OR ≥ 10 mm spiral CT scan No known brain metastasis leptomeningeal disease Hormone receptor status specify PATIENT CHARACTERISTICS : Male female patient Menopausal status specify Life expectancy ≥ 12 week ECOG performance status 01 WBC ≥ 3,000/mm^3 Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Bilirubin normal AST/ALT ≤ 2.5 time upper limit normal Creatinine normal OR creatinine clearance ≥ 60 mL/min LVEF ≥ 50 % Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Able swallow retain oral medication No history allergic reaction attribute compound similar chemical biologic composition lapatinib No gastrointestinal ( GI ) tract disease result inability take oral medication No malabsorption syndrome requirement IV alimentation No uncontrolled inflammatory GI disease ( e.g. , Crohn 's disease , ulcerative colitis ) PRIOR CONCURRENT THERAPY : Prior trastuzumab ( Herceptin ® ) allow Prior anthracyclines allow provided total dose doxorubicin hydrochloride ≤ 240 mg/m² epirubicin ≤ 600 mg/m² More 4 week since prior major surgery , hormonal therapy ( replacement therapy ) , chemotherapy ( 6 week nitrosoureas mitomycin C ) , radiotherapy recover No prior surgical procedure affect absorption No prior EGFRtargeting therapy At least 7 day since prior concurrent CYP3A4 inhibitor At least 7 day since prior concurrent gastric pH modifier Antacids allow within 1 hour lapatinib dose At least 14 day since prior concurrent CYP3A4 inducer , include dexamethasone dexamethasone equivalent dose &gt; 1.5 mg/day At least 6 month since prior concurrent amiodarone No concurrent combination antiretroviral therapy HIVpositive patient No concurrent prophylactic growth factor support No concurrent herbal medications No concurrent investigational agent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>male breast cancer</keyword>
</DOC>